Ⅰ期非小细胞肺癌p53蛋白的表达及其临床意义

Clinical study of p53 protein in Patinents with stage Ⅰ non small cell lung cancer

目的 :研究 48例Ⅰ期非小细胞肺癌 (NSCLC)p5 3蛋白的表达 ,试图为早期肺癌找到灵敏、特异的指标 ,以指导术后治疗。方法 :收集手术后原发灶的石腊标本及其临床、随访资料 ,以p5 3单抗为探针 ,采用免疫组化S P (streptavidin peroxidase)法检测原发灶p5 3蛋白的表达。结果 :48例Ⅰ期NSCLC患者中 2 3例(47 9% )阳性 ,p5 3(+)组五年生存率为 30 4% (7/ 2 3) ,p5 3(- )组为 72 0 % (18/ 2 5 ) ,χ2 检验P <0 0 1,生存分析log rank检验P <0 0 1;无病生存期明确的 37例患者中p5 3(+)组无病生存率为 40 0 % (6 / 15 ) ,p5 3(- )组无病生存率为 77 3% (17/ 2 2 ) ,χ2 检验P <0 0 5 ,生存分析log rank检验P <0 0 5。结论 :p5 3(+)组的生存期及无病生存期均明显短于p5 3(- )组。免疫组化法检测Ⅰ期NSCLC患者原发灶p5

Purpose:To find the sensitive and special factor of prognosis, and to guide postoperative treatment.Methods:The p53 protein of 48 patients with non small cell lung cancer (NSCLC) in stage I were detected. The paraffin embedded tumor section samples of 48 patients were collected. The clinical materials and follow up information of all 48 patients were obtained. The immunohistochemical staining method,strepatavidin peroxidase(S P)method,was used to detect the p53 protein in primary tumor tissue using the p53 monoclonal antibody. Results:The p53 protein were positive in 23(47.9%) of 48 patients. The postoperative 5 year survival rate in p53(+) group was 30.4% (7/23),and in p53(-) group was 72.0% (18/25)(χ 2 test, P <0 01). Survival time of two groups were compared by log rank test, P <0 01. In 37 patients with known disease free survival time,the postoperative disease free survival rate in p53(-) group was 77.3% (17/22),and in p53(+) group was 40.0% (6/15)(χ 2 test, P <0 05). Survival analysis by log rank test, P <0 05.Conclusions:The results show that positiveness of p53 in primary tumor tissue in patients with stage Ⅰ NSCLC is associated with decreased survival time and disease free survival time.The detection of p53 in primary tumor tissue of patients with stage Ⅰ NSCLC by immunohistology method is obviously of clinical significance.